Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRILLIANT-1
NCT06501378Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Primary endpoint: Overall Survival at 1 year. Started Jul 2024; status: completed.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06501378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501378.